Lipidor AB — Investor Relations & Filings

Lipidor AB was a pharmaceutical development company focused on topical medications for skin diseases. The company's core was its proprietary AKVANO technology, a water-free, lipid-based, sprayable drug delivery platform. This technology was designed to enhance the delivery of active pharmaceutical ingredients for treating conditions such as psoriasis, acne vulgaris, and bacterial skin infections, while offering a convenient alternative to traditional creams and ointments. The company's pipeline included product candidates that had reached late-stage clinical development, such as AKP02 for the treatment of psoriasis. In May 2025, the company filed for bankruptcy.